Protara Therapeutics Plummets 20.7%: Equity Raise Sparks Investor Exodus

Summary
• Protara Therapeutics (TARA) slumps 20.7% intraday after announcing a $75M equity offering.
• Pre-market drop of 16% signals investor skepticism over dilution risks.
• Funds will fund TARA-002 development and general corporate purposes.

Protara Therapeutics’ stock has imploded on Friday, trading at $5.445—a 20.7% decline from its previous close of $6.87. The sharp selloff follows the company’s announcement of a $75M public offering, sparking immediate concerns over equity dilution. With a day range of $5.07 to $5.59, the stock’s volatility underscores a critical juncture for the biotech firm as it seeks capital to advance its bladder cancer therapy, TARA-002.

Equity Offering Triggers Investor Flight
Protara’s 20.7% intraday plunge is directly tied to its $75M public offering, priced at $5.75 per share. The offering, which includes 13.04 million shares and a 30-day over-allotment option, has been interpreted as a dilutive move that erodes shareholder value. Pre-market trading saw the stock drop 16% to $5.77, reflecting immediate skepticism. Investors are wary of the 14.3% turnover rate and the company’s negative PE ratio (-3.93), which amplify concerns over capital efficiency. The offering’s proceeds will fund TARA-002’s clinical development, but the aggressive dilution has overshadowed recent positive data from the Phase II ADVANCED-2 trial, where TARA-002 showed 72% complete response rates in BCG-naïve patients.

Biotech Sector Splits as AMGN Drags Down Peers
The biotech sector remains mixed, with Amgen (AMGN) down 2.59% and peers like PHVS and VTYX up 5.31% and 8.25%, respectively. Protara’s 20.7% drop contrasts sharply with the sector’s resilience, highlighting investor caution around dilutive capital raises. While AMGN’s decline reflects broader market jitters, Protara’s selloff is more directly tied to its equity offering. The sector’s divergence underscores the fragility of biotech stocks under dilution pressure, particularly for companies like Protara with high R&D costs and unproven commercialization timelines.

Bearish Playbook: Puts and Long-Dated Calls in Focus
• MACD: 0.509 (bullish divergence), Signal Line: 0.527 (bearish crossover), Histogram: -0.018 (bearish momentum)
• RSI: 66.33 (neutral), Bollinger Bands: $4.02–$8.35 (wide range), 200D MA: $3.96 (below current price)
• Support/Resistance: $5.07–$5.14 (short-term support), $3.07–$3.16 (long-term floor)

Protara’s technicals paint a volatile picture. The 200-day average ($3.96) is far below the current price ($5.45), suggesting a potential rebound. However, the bearish MACD crossover and RSI neutrality indicate caution. Key levels to watch: $5.07 (intraday low) and $3.07 (200D support).

Top Options:
• TARA20251219P5 (Put, $5 strike, Dec 19 expiry):
- IV: 72.27% (high volatility)
- Leverage: 41.88% (aggressive downside potential)
- Delta: -0.25 (moderate sensitivity)
- Theta: -0.004 (slow time decay)
- Turnover: $13,898 (liquid)
- Gamma: 0.40 (high sensitivity to price swings)
This put option offers a 41.88% leverage ratio and 72.27% implied volatility, ideal for a short-term bearish bet. With $13,898 turnover, liquidity is robust, and the high gamma ensures responsiveness to price swings.

• TARA20260515C5 (Call, $5 strike, May 15 expiry):
- IV: 97.33% (moderate volatility)
- Leverage: 3.40% (conservative bullish play)
- Delta: 0.69 (strong directional bias)
- Theta: -0.004 (slow decay)
- Turnover: $53,616 (high liquidity)
- Gamma: 0.10 (moderate sensitivity)
This long-dated call provides a 3.40% leverage ratio and 97.33% IV, balancing risk and reward. The $53,616 turnover ensures ease of entry/exit, while the 0.69 delta aligns with a potential rebound above $5.07 support.

Payoff Estimation:
- Put (TARA20251219P5): A 5% downside to $5.175 would yield a $0.825 payoff (strike price $5 vs. $5.175).
- Call (TARA20260515C5): A 5% rebound to $5.717 would yield a $0.717 payoff (strike price $5 vs. $5.717).

Action Insight: Aggressive bears should target TARA20251219P5 for a short-term play, while bulls may consider TARA20260515C5 for a long-term rebound. If $5.07 breaks, the put offers immediate upside; above $5.14, the call gains traction.

Backtest Protara Therapeutics Stock Performance
I attempted to retrieve the necessary price series but the data source did not return any information for the query I used. To continue, I have two options:1. Approximate the “-21 % intraday plunge” by using daily close-to-close returns ≤ -21 %. 2. Attempt another query that fetches daily OHLC data (open / high / low / close) and flag days where the day’s low is ≤ -21 % below the previous close. This is a closer match to a true “intraday” drop, but depends on whether the OHLC feed is available for TARA.Please let me know which approach you prefer (or provide a list of the specific event dates if you already have them), and I’ll proceed with the back-test accordingly.

Protara at Crossroads: Watch $5.07 Support for Clarity
Protara’s 20.7% selloff reflects investor unease over dilution, but the stock’s technicals and long-dated options suggest a potential rebound. The $5.07 intraday low is a critical support level; a break below this could trigger further declines toward $3.07. Conversely, a rebound above $5.14 may reignite interest in TARA-002’s clinical progress. Sector leader Amgen (AMGN) is down 2.59%, signaling broader biotech caution. Investors should monitor the $5.07 threshold and consider the TARA20251219P5 put for a bearish play or the TARA20260515C5 call for a long-term bet. The offering’s success and TARA-002’s Phase II data in Q1 2026 will be pivotal. Act now: Secure puts if $5.07 breaks, or hold calls for a potential bounce.